What was the market valuation of the US organoids market in 2024?

The market valuation of the US organoids market was $470.4 Million in 2024. Read More

What is the projected market valuation for the US organoids market by 2035?

The projected market valuation for the US organoids market is $1335.25 Million by 2035. Read More

What is the expected CAGR for the US organoids market during the forecast period 2025 - 2035?

The expected CAGR for the US organoids market during the forecast period 2025 - 2035 is 9.95%. Read More

Which application segment had the highest valuation in 2024?

In 2024, the regenerative medicine application segment had the highest valuation at $150.0 Million. Read More

What are the projected valuations for the disease modeling application segment by 2035?

The projected valuation for the disease modeling application segment is $350.0 Million by 2035. Read More

Which type of organoid is expected to have the highest growth in the coming years?

Lung organoids, with a valuation of $160.4 Million in 2024, are expected to show significant growth. Read More

What was the valuation of the pharmaceutical companies segment in 2024?

The valuation of the pharmaceutical companies segment was $188.16 Million in 2024. Read More

How do research institutions contribute to the US organoids market?

Research institutions contributed $141.12 Million to the US organoids market in 2024. Read More

What is the expected valuation for human tissue as a source by 2035?

The expected valuation for human tissue as a source is $450.0 Million by 2035. Read More

Which key players are leading the US organoids market?

Key players leading the US organoids market include Organovo Holdings Inc, TissUse GmbH, and Mimetas B.V. Read More

What is the projected market value of the US Organoids Market by 2035?

By 2035, the projected market value of the US Organoids Market is anticipated to reach 3,330.0 million USD. Read More

Which product segment is expected to dominate in the US Organoids Market by 2035?

The product segment is expected to dominate with a market value of 1,780.0 million USD by 2035. Read More

What are the expected revenue figures for the service segment in the US Organoids Market by 2035?

The service segment is anticipated to generate revenue of 1,550.0 million USD by 2035. Read More

What major trend is expected to influence the US Organoids Market from 2025 to 2035?

Rising investments in organoid technology for drug development is a major trend influencing the market. Read More

How does the US Organoids Market growth rate compare across different segments?

The growth rate of the service segment is expected to closely follow that of the product segment during the forecasted period. Read More

What are the key applications driving the US Organoids Market growth?

Key applications driving growth include drug discovery, disease modeling, and regenerative medicine. Read More

How may the competitive landscape of the US Organoids Market evolve by 2035?

The competitive landscape is expected to evolve with increased collaboration among major players and new entrants focusing on innovation. Read More

US Organoids Market

ID: MRFR/MED/43366-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Organoids Market Research Report By Product (Product, Service), By Type of organoids (Liver, Kidney, Pancreas, Intestine, Others), By Application (Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, Others) and By End-user (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Others) -Forecast to 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Drug Discovery
  2. 4.1.2 Disease Modeling
  3. 4.1.3 Regenerative Medicine
  4. 4.1.4 Toxicity Testing
2. 4.2 Healthcare, BY Type (USD Million)
  1. 4.2.1 Intestinal Organoids
  2. 4.2.2 Liver Organoids
  3. 4.2.3 Brain Organoids
  4. 4.2.4 Lung Organoids
3. 4.3 Healthcare, BY End User (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Research Institutions
  3. 4.3.3 Academic Institutions
  4. 4.3.4 Biotechnology Companies
4. 4.4 Healthcare, BY Source (USD Million)
  1. 4.4.1 Human Tissue
  2. 4.4.2 Animal Tissue
  3. 4.4.3 Stem Cells
  4. 4.4.4 Induced Pluripotent Stem Cells
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Organovo Holdings Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 TissUse GmbH (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Mimetas B.V. (NL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 InSphero AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Stemcell Technologies Inc (CA)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 3D Biotek LLC (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Regenhu Ltd (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Cellink AB (SE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY END USER
5. 6.5 US MARKET ANALYSIS BY SOURCE
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY TYPE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY END USER, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY SOURCE, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY SOURCE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
  4. 7.2.4 BY SOURCE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

Drug Discovery
Disease Modeling
Regenerative Medicine
Toxicity Testing

Healthcare By Type (USD Million, 2025-2035)

Intestinal Organoids
Liver Organoids
Brain Organoids
Lung Organoids

Healthcare By End User (USD Million, 2025-2035)

Pharmaceutical Companies
Research Institutions
Academic Institutions
Biotechnology Companies

Healthcare By Source (USD Million, 2025-2035)

Human Tissue
Animal Tissue
Stem Cells
Induced Pluripotent Stem Cells

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”